Irinotecan trials for Colorectal cancer

All Irinotecan trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Irinotecan for Colorectal cancer

• 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
  NCT04689347 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
  NCT07543744 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
  NCT07474727 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 19 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP1002 in Adults for Treatment of Solid Tumors
  NCT05719558 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
  NCT05379595 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 251 locations
• AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
  NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
  NCT06547203 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Efficacy of Hyperthermic Intraperitoneal Chemotherapy
  NCT04861558 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 5 locations
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
  NCT05727163 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
  NCT05391126 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
  NCT06509126 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
  NCT05462236 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
  NCT04329494 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
  NCT03715933 · Phase: Phase 1 · Ages: 12 Years to 85 Years · Sex: All (male and female) · 36 locations
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
  NCT06974110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
  NCT07775287 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
  NCT04920032 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
  NCT02885753 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
  NCT05863195 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
  NCT05628038 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
  NCT06714357 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations

Common questions

How many trials study Irinotecan for Colorectal cancer?

24 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.